Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P00748

UPID:
FA12_HUMAN

ALTERNATIVE NAMES:
Hageman factor

ALTERNATIVE UPACC:
P00748; P78339

BACKGROUND:
The protein Coagulation factor XII, or Hageman factor, plays a pivotal role in initiating blood coagulation, fibrinolysis, and the production of bradykinin and angiotensin. It activates prekallikrein to kallikrein, which then cleaves factor XII, leading to the activation of factor XI and progression of the coagulation pathway.

THERAPEUTIC SIGNIFICANCE:
Linked to Factor XII deficiency and Hereditary angioedema type 3, Coagulation factor XII's genetic variants underscore its clinical importance. Exploring the function of Coagulation factor XII offers promising avenues for developing targeted treatments for these diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.